{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:27Z","timestamp":1794475767537,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["101102733"],"award-info":[{"award-number":["101102733"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vaccine.2026.128688","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:07:23Z","timestamp":1778620043000},"page":"128688","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Modeling optimal deployment strategies for Nipah vaccines and monoclonal antibodies"],"prefix":"10.1016","volume":"84","author":[{"given":"Oscar","family":"Cortes-Azuero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Vegvari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Roney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Scarponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christinah","family":"Mukandavire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Cauchemez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Salje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128688_bb0005","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMoa1805376","article-title":"Transmission of Nipah virus - 14 years of investigations in Bangladesh","volume":"380","author":"Nikolay","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vaccine.2026.128688_bb0010","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41564-025-02020-9","article-title":"A one health approach to understanding and managing Nipah virus outbreaks","volume":"10","author":"Yadav","year":"2025","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128688_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11908-006-0036-2","article-title":"Nipah virus: impact, origins, and causes of emergence","volume":"8","author":"Epstein","year":"2006","journal-title":"Curr. Infect. Dis. Rep."},{"key":"10.1016\/j.vaccine.2026.128688_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011617","article-title":"Tackling a global epidemic threat: Nipah surveillance in Bangladesh, 2006\u20132021","volume":"17","author":"Satter","year":"2023","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.vaccine.2026.128688_bb0025","series-title":"Annual Review of Diseases Prioritized under the Research and Development Blueprint","author":"World Health Organization","year":"2018"},{"key":"10.1016\/j.vaccine.2026.128688_bb0030","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/14760584.2025.2476523","article-title":"Progress and challenges in Nipah vaccine development and licensure for epidemic preparedness and response","volume":"24","author":"Kim","year":"2025","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.vaccine.2026.128688_bb0035","series-title":"New Vaccine Set for Human Trials in Nipah Outbreak Hotspot","author":"Coalition for Epidemic Preparedness Innovations (CEPI)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128688_bb0040","series-title":"Nipah Vaccines Set to Enter Human Trials","author":"Joi","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128688_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanmic.2024.101002","article-title":"Therapeutics for Nipah virus disease: a systematic review to support prioritisation of drug candidates for clinical trials","volume":"6","author":"Chan","year":"2025","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.vaccine.2026.128688_bb0050","series-title":"New Human Trials for Novel Antibody Offer Hope for Immediate Protection Against Deadly Nipah","author":"Coalition for Epidemic Preparedness Innovations (CEPI)","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128688_bb0055","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1016\/j.vaccine.2021.08.027","article-title":"Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh","volume":"39","author":"Nikolay","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128688_bb0125","doi-asserted-by":"crossref","first-page":"S363","DOI":"10.1093\/infdis\/jiaa074","article-title":"A framework to monitor changes in transmission and epidemiology of emerging pathogens: lessons from Nipah virus","volume":"221","author":"Nikolay","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.vaccine.2026.128688_bb0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1098\/rsif.2011.0223","article-title":"Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis","volume":"9","author":"Pulliam","year":"2012","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.vaccine.2026.128688_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001399","article-title":"Using routine surveillance data to estimate the epidemic potential of emerging zoonoses: application to the emergence of US swine origin influenza A H3N2v virus","volume":"10","author":"Cauchemez","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.vaccine.2026.128688_bb0080","series-title":"Update: Outbreak of Nipah Virus -- Malaysia and Singapore, 1999","author":"Centers for Disease Control and Prevention (CDC)","year":"1999"},{"key":"10.1016\/j.vaccine.2026.128688_bb0065","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128688_bb0070","series-title":"odin2: Next Generation Odin","author":"R","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128688_bb0075","series-title":"dust2: Next Generation Dust","author":"FitzJohn","year":"2025"},{"key":"10.1016\/j.vaccine.2026.128688_bb0085","series-title":"Japanese Encephalitis\/Nipah Outbreak in Malaysia","author":"Food and Agriculture Organization of the United Nations (FAO)-World Health Organization (WHO) Global Forum of Food Safety Regulators","year":"2002"},{"key":"10.1016\/j.vaccine.2026.128688_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106398","article-title":"Malaysia outbreak survivors retain detectable Nipah antibodies and memory B cells after 25 years","volume":"90","author":"Ong","year":"2025","journal-title":"J. Infect."},{"key":"10.1016\/j.vaccine.2026.128688_bb0090","series-title":"Health Labour Market Analysis in Bangladesh 2021","author":"Ministry of Health and Family Welfare of the People'\u2019s Republic of Bangladesh","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128688_bb0095","series-title":"Bangladesh Health Workforce Strategy 2023\u20132041","author":"Ministry of Health and Family Welfare-Government of the People\u2019\u2019s Republic of Bangladesh","year":"2023"},{"key":"10.1016\/j.vaccine.2026.128688_bb0100","doi-asserted-by":"crossref","first-page":"eadl2055","DOI":"10.1126\/scitranslmed.adl2055","article-title":"Therapeutic administration of a cross-reactive mAb targeting the fusion glycoprotein of Nipah virus protects nonhuman primates","volume":"16","author":"Zeitlin","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.vaccine.2026.128688_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/ana.21178","article-title":"Long-term neurological and functional outcome in Nipah virus infection","volume":"62","author":"Sejvar","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.vaccine.2026.128688_bb0110","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/ana.10212","article-title":"Relapsed and late-onset Nipah encephalitis","volume":"51","author":"Tan","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.vaccine.2026.128688_bb0115","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/S2214-109X(15)00069-8","article-title":"Disability weights for the global burden of disease 2013 study","volume":"3","author":"Salomon","year":"2015","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.vaccine.2026.128688_bb0120","doi-asserted-by":"crossref","DOI":"10.3346\/jkms.2019.34.e60","article-title":"Disability weights measurement for 289 causes of disease considering disease severity in Korea","volume":"34","author":"Ock","year":"2019","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.vaccine.2026.128688_bb0135","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrmicro.2017.45","article-title":"Pathways to zoonotic spillover","volume":"15","author":"Plowright","year":"2017","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.vaccine.2026.128688_bb0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s44360-025-00027-4","article-title":"A framework for risk\u2013benefit analysis of vaccines approved through accelerated pathways","volume":"1","author":"Cracknell Daniels","year":"2026","journal-title":"Nat. Health"},{"key":"10.1016\/j.vaccine.2026.128688_bb0145","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiae221","article-title":"The genetic diversity of Nipah virus across spatial scales","author":"Cortes-Azuero","year":"2024","journal-title":"J. Infect. Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26004962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:59:14Z","timestamp":1794473954000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26004962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S0264410X26004962"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128688","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modeling optimal deployment strategies for Nipah vaccines and monoclonal antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128688","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128688"}}